Archives
Review | Voice restoration in mechanically ventilated intensive care unit patients with a tracheostomy
9 Jan, 2023 | 13:44h | UTC
WHO manual on sugar-sweetened beverage taxation policies to promote healthy diets.
16 Dec, 2022 | 13:52h | UTCNews Release: WHO calls on countries to tax sugar-sweetened beverages to save lives – World Health Organization
Related:
M-A: Outcomes following taxation of sugar-sweetened beverages.
Public Policies to Reduce Sugary Drink Consumption in Children and Adolescents – Pediatrics
Cutting back on sugar-sweetened beverages: What works? – Cochrane Library
Sugar-sweetened beverage taxes: Lessons to date and the future of taxation – PLOS Medicine
Banning the promotion of soft drinks could be more effective than a sugar tax – The Conversation
Sugar tax: why health experts want it but politicians and industry are resisting – The Guardian
Commentary on Twitter
Sugar is addictive and keeps you hooked on unhealthy drinks like sodas & energy drinks.
Break the cycle today for a healthier life! https://t.co/M1GQE4136I pic.twitter.com/06aVCYmeK5— World Health Organization (WHO) (@WHO) December 13, 2022
RCT | Chlorthalidone (12.5-25 mg) and Hydrochlorothiazide (25-50 mg) are similarly effective for the prevention of CVD in hypertensive patients.
16 Dec, 2022 | 13:49h | UTCChlorthalidone vs. Hydrochlorothiazide for Hypertension–Cardiovascular Events – New England Journal of Medicine (link to abstract – $ for full-text)
Related (news release and commentaries before publication): RCT | Chlortalidone and Hydrochlorothiazide resulted in similar reductions of CVD in older patients with hypertension.
Commentary on Twitter
Patients 65 years or older with hypertension who switched from chlorthalidone to hydrochlorothiazide did not have fewer major cardiovascular events or non–cancer-related deaths than those who continued receiving hydrochlorothiazide. https://t.co/9xAiSZzxio pic.twitter.com/bIVOOiVDve
— NEJM (@NEJM) December 14, 2022
Cohort Study | Association of the triglyceride glucose index as a measure of insulin resistance with mortality and CVD
9 Jan, 2023 | 13:42h | UTCInvited Commentary: The triglyceride glucose index and cardiovascular disease outcomes – The Lancet Health Longevity
Updated Guidance | Acute, periprocedural and long-term antithrombotic therapy in older adults.
16 Dec, 2022 | 13:51h | UTCCommentary: Antithrombotic Therapy in Older Adults: Key Points – American College of Cardiology
Cohort Study | Association between bariatric surgery and alcohol use–related hospitalization and all-cause mortality.
16 Dec, 2022 | 13:44h | UTCAssociation Between Bariatric Surgery and Alcohol Use–Related Hospitalization and All-Cause Mortality in a Veterans Affairs Cohort – JAMA Surgery (link to abstract – $ for full-text)
RCTs | Vaccines for Zaire Ebola virus disease.
16 Dec, 2022 | 13:46h | UTCRandomized Trial of Vaccines for Zaire Ebola Virus Disease – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Ebola vaccine regimens safe, immunogenic in adults and children – NIH News Releases
Commentaries:
Ebola vaccine strategies show safety and immune response – CIDRAP
Commentary on Twitter
In two randomized trials of Ebola vaccines, safety and immune responses in adults and children were assessed for three regimens with two different vaccines. All three induced immune responses lasting at least 1 year. https://t.co/JUMN8Ieygv pic.twitter.com/NajlnA2B7y
— NEJM (@NEJM) December 14, 2022
RCT | Effect of an intermittent calorie-restricted diet on Type 2 DM remission.
16 Dec, 2022 | 13:43h | UTCEffect of an Intermittent Calorie-restricted Diet on Type 2 Diabetes Remission: A Randomized Controlled Trial – The Journal of Clinical Endocrinology & Metabolism (link to abstract – $ for full-text)
Commentaries:
Expert reaction to study looking at intermittent fasting and type 2 diabetes – Science Media Centre
Intermittent Fasting Can Achieve Remission in Type 2 Diabetes – HealthDay
Commentary on Twitter
Can an intermittent fasting (IF) diet reverse Type 2 diabetes?
A small randomized trial says yes, w/ 47% of IF-assigned participants achieving remission for at least 1 year vs 3% of controls (odds ratio of 31; yes, too good to be true)https://t.co/Ths3LrNL8u
Worth further study pic.twitter.com/VwOqMeAAJr— Eric Topol (@EricTopol) December 14, 2022
Incidence and burden of injury at the Tokyo 2020 Paralympic Games held during the COVID-19 pandemic.
16 Dec, 2022 | 13:40h | UTCNews Release: Fewer, but more serious, injuries at Tokyo 2020 Paralympics than at previous Games – British Journal of Sports Medicine
New sports, COVID-19 and the heat: sports injuries and illnesses in the Tokyo 2020 Summer Olympics.
16 Dec, 2022 | 13:41h | UTCNews Release: Some ‘new’ sports linked to highest injury rates at 2020 Tokyo Olympics – BMJ Newsroom
Guideline | ADA 2023 Standards of Medical Care in Diabetes.
14 Dec, 2022 | 15:59h | UTCGuideline Homepage: ADA 2023 Standards of Medical Care in Diabetes – American Diabetes Association
Introduction: Standards of Medical Care in Diabetes—2023
Summary of Revisions: Standards of Medical Care in Diabetes—2023
- Improving Care and Promoting Health in Populations: Standards of Care in Diabetes—2023
- Classification and Diagnosis of Diabetes: Standards of Care in Diabetes—2023
- Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2023
- Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2023
- Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes—2023
- Glycemic Targets: Standards of Care in Diabetes—2023
- Diabetes Technology: Standards of Care in Diabetes—2023
- Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes—2023
- Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023
- Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023
- Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2023
- Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2023
- Older Adults: Standards of Care in Diabetes—2023
- Children and Adolescents: Standards of Care in Diabetes—2023
- Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2023
- Diabetes Care in the Hospital: Standards of Care in Diabetes—2023
- Diabetes Advocacy: Standards of Care in Diabetes—2023
2022 ACR/EULAR classification criteria for giant cell arteritis.
16 Dec, 2022 | 13:39h | UTCNews Release: Updated: GCA Classification Criteria – European Alliance of Associations for Rheumatology
Intrapatient RCT | Beremagene Geperpavec (B-VEC) vs. placebo for dystrophic epidermolysis bullosa.
16 Dec, 2022 | 13:34h | UTCTrial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa – New England Journal of Medicine (link to abstract – $ for full-text)
RCT | A remotely delivered self-directed behavioral intervention resulted in little weight loss in adults with obesity.
16 Dec, 2022 | 13:38h | UTCEffect of a Remotely Delivered Self-directed Behavioral Intervention on Body Weight and Physical Health Status Among Adults With Obesity: The D-ELITE Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: The Challenge of Defining the Optimal Lifestyle Weight Loss Intervention for Real-world Settings – JAMA (free for a limited period)
Commentary from the author on Twitter (thread – click for more)
https://twitter.com/KateHoerster/status/1602703023738064897
RCT | Effect of diet and exercise on knee pain in patients with osteoarthritis and overweight or obesity.
16 Dec, 2022 | 13:36h | UTCEffect of Diet and Exercise on Knee Pain in Patients With Osteoarthritis and Overweight or Obesity: A Randomized Clinical Trial – JAMA (free for a limited period)
See also: Visual Abstract
RCT | Efficacy and safety of azithromycin vs. placebo to treat lower respiratory tract infections associated with low procalcitonin.
16 Dec, 2022 | 13:30h | UTCEfficacy and safety of azithromycin versus placebo to treat lower respiratory tract infections associated with low procalcitonin: a randomised, placebo-controlled, double-blind, non-inferiority trial – The Lancet Infectious Diseases (link to abstract – $ for full-text)
Commentary on Twitter
New research: Efficacy and safety of azithromycin versus placebo to treat lower respiratory tract infections associated with low procalcitonin: a randomised, placebo-controlled, double-blind, non-inferiority trialhttps://t.co/EZW7YdxPPU pic.twitter.com/4zlsVN5NtT
— The Lancet Infectious Diseases (@TheLancetInfDis) December 14, 2022
RCT | Zanubrutinib vs. Ibrutinib in relapsed or refractory chronic lymphocytic leukemia.
16 Dec, 2022 | 13:33h | UTCZanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Zanubrutinib Found Superior to Ibrutinib for CLL and SLL – The ASCO Post
RCT | The addition of Olanzapine to a triple antiemetic regimen effectively prevents nausea and vomiting during highly emetogenic chemotherapy.
16 Dec, 2022 | 13:32h | UTCRelated:
Phase 1b/2a Study | Safety, pharmacokinetics, and pharmacodynamics of Pegozafermin in patients with non-alcoholic steatohepatitis.
16 Dec, 2022 | 13:29h | UTCSafety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)
Commentary on Twitter
New research – Loomba et al – Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a study https://t.co/49u1OQKSRJ#livertwitter #NASH #fattyliver @DrLoomba pic.twitter.com/2emqc8Qkfw
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) December 13, 2022
Review | Human papillomavirus vaccination and cervical cancer risk.
16 Dec, 2022 | 13:26h | UTCHuman papillomavirus vaccination and cervical cancer risk – The BMJ
Review | Advances in diagnosis and treatment of testicular cancer.
16 Dec, 2022 | 13:25h | UTCAdvances in diagnosis and treatment of testicular cancer – The BMJ
Review | Pathophysiology, diagnosis, and management of endometriosis.
16 Dec, 2022 | 13:23h | UTCPathophysiology, diagnosis, and management of endometriosis – The BMJ
Review | Conducting umbrella reviews.
16 Dec, 2022 | 13:21h | UTCConducting umbrella reviews – BMJ Medicine
Review | Endometrial cancer: molecular classification and future treatments.
16 Dec, 2022 | 13:20h | UTCEndometrial cancer: molecular classification and future treatments – BMJ Medicine
Commentary on Twitter
The latest #review by Bradley Corr and colleagues concludes that the development of molecular analysis combined with novel agents and new drug classes have revolutionised #precisionmedicine for patients with endometrial #cancer. Read now ▶️ https://t.co/TaNgrM2EWl#MedTwitter pic.twitter.com/GexXdLzlQH
— BMJMedicine (@BMJMedicine) December 9, 2022
M-A | Vestibular suppressants do not reduce symptoms in patients with benign paroxysmal positional vertigo.
16 Dec, 2022 | 13:18h | UTCVestibular suppressants for benign paroxysmal positional vertigo: A systematic review and meta-analysis of randomized controlled trials – Academic Emergency Medicine (link to abstract – $ for full-text)